Novo Nordisk A/S (NVO) Says Obesity Drug Trial Confirms Weight Loss
Friday, May 24, 2013
More...
|
Zealand Pharma - Announcement of Transactions in the Company’s Shares and Related Securities by Executives and Their Related Parties
Thursday, May 23, 2013
More...
|
BioPorto’s NGAL Cut-Off Patent - Processing of the Appeal in the Opposition Case
Thursday, May 23, 2013
More...
|
European Medicines Agency Accepts Veloxis Pharmaceuticals A/S (VELO)' Marketing Authorization Application (MAA) for LCP-Tacro for Treatment of Kidney Transplant Patients
Wednesday, May 22, 2013
More...
|
H. Lundbeck A/S (LUN.CO) Release: Vortioxetine, a New Multimodal Agent in Development for the Treatment of Major Depression, Shows Effects on Cognitive Function in Several Preclinical Animal Models
Wednesday, May 22, 2013
More...
|
H. Lundbeck A/S (LUN.CO) – Admittance to Trading and Official Listing of New Shares Due to Exercise of Warrants
Tuesday, May 21, 2013
More...
|
Zealand Pharma to Present at Upcoming Global Healthcare Investor Conferences in the U.S.
Tuesday, May 21, 2013
More...
|
Old Scizophrenia Medicine Works on Antibiotics-Resistant Bacteria, University of Southern Denmark Study
Tuesday, May 21, 2013
More...
|
Veloxis Pharmaceuticals A/S (VELO) Release: Final STRATO Clinical Study Data Demonstrates Potential for LCP-Tacro™ to Improve Tacrolimus-Induced Tremors
Monday, May 20, 2013
More...
|
Lundbeck Inc. (LUN.CO) Release: Vortioxetine Clinical Phase III Data Show Significant Improvement in Symptoms of Major Depression
Monday, May 20, 2013
More...
|
|